CLAIMS

1. An aqueous cagrilintide formulation comprising:
   - cagrilintide;
   - a buffer which is: glutamic acid/glutamate, in a concentration of about 2-10 mM; or lactic acid/lactate, in a concentration of about 2-35 mM; or acetic acid/acetate, in a concentration of about 2-10 mM;
   - 90-99% w/w water; and
   - a pH of 3.5-4.5, such as about pH 4.0.

2. An aqueous cagrilintide formulation comprising:
   - cagrilintide in a concentration of 0.1-20 mg/ml;
   - a buffer which is: glutamic acid/glutamate, in a concentration of about 2-10 mM; or lactic acid/lactate, in a concentration of about 2-35 mM; or acetic acid/acetate, in a concentration of about 2-10 mM; and
   - a pH of 3.5-4.5, such as about pH 4.0.

3. The cagrilintide formulation according to any one of claims 1-2, wherein the buffer is glutamic acid/glutamate in a concentration of 2-10 mM, such as 2.5-10 mM, such as 2.5-5 mM, such as 5-10 mM, such as 2-9 mM, such as 2-8 mM, such as 2.5-7.5 mM, such as 2-7 mM, such as 2-6 mM, such as 4-6 mM, such as about 5 mM.

4. The cagrilintide formulation according to any one of claims 1-3, further comprising a tonicity agent, such as glycerol, mannitol, propylene glycol, sorbitol, sucrose or trehalose.

5. The cagrilintide formulation according to any one of claims 1-4 for use in an injection device.

6. The cagrilintide formulation according to any one of claims 1-5 for use in medicine.

7. An aqueous semaglutide formulation comprising:
   - semaglutide;
   - phosphate, in a concentration of more than 15 mM and less than or equal to 45 mM, such as 16-45 mM, such as 20-45 mM, such as 20-40 mM, such as 25-45

mM, such as 25-40 mM, such as 20-35 mM, such as 20-30 mM, such as 25-35 mM, such as about 30 mM;
- 90-99% w/w water; and
- a pH of 7.0-8.0, such as about 7.4.

8. An aqueous semaglutide formulation comprising:
- semaglutide, in a concentration of 0.1-10 mg/ml;
- phosphate, in a concentration of more than 15 mM and less than or equal to 45 mM, such as 16-45 mM, such as 20-45 mM, such as 20-40 mM, such as 25-45 mM, such as 25-40 mM, such as 20-35 mM, such as 20-30 mM, such as 25-35 mM, such as about 30 mM; and
- a pH of 7-8, such as about 7.4.

9. The semaglutide formulation according to any one of claims 7-8, further comprising histidine.

10. The semaglutide formulation according to any one of claims 7-9, further comprising a tonicity agent, such as propylene glycol, potassium chloride and/or sodium chloride.

11. The semaglutide formulation according to any one of claims 7-10 for use in an injection device.

12. The semaglutide formulation according to any one of claims 7-10, optionally in combination with the cagrilintide formulation according to any one of claims 1-4, for use in medicine.

13. A medical device comprising semaglutide in a first chamber and cagrilintide in a second chamber.

14. A medical device comprising a first chamber and a second chamber, wherein the first chamber comprises the semaglutide formulation according to any one of claims 7-10and the second chamber comprises the cagrilintide formulation according to any one of claims 1-4.

15. The medical device according to claim 14, wherein the first chamber is a distal chamber and the second chamber is a proximal chamber.

16. A fixed-dose combination of 0.025-5.0 mg cagrilintide and 0.05-5.0 mg semaglutide for use in medicine, wherein the cagrilintide and semaglutide are administered parenterally, such as subcutaneously, in a single injection.